Cargando…
Enduring neurological sequelae of benzodiazepine use: an Internet survey
INTRODUCTION: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated. OBJECTIVE:...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905027/ https://www.ncbi.nlm.nih.gov/pubmed/36760692 http://dx.doi.org/10.1177/20451253221145561 |
_version_ | 1784883744297975808 |
---|---|
author | Huff, Christy Finlayson, A. J. Reid Foster, D. E. Martin, Peter R. |
author_facet | Huff, Christy Finlayson, A. J. Reid Foster, D. E. Martin, Peter R. |
author_sort | Huff, Christy |
collection | PubMed |
description | INTRODUCTION: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated. OBJECTIVE: This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation. METHODS: An online survey (n = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms. RESULTS: The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal. CONCLUSIONS: These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users. |
format | Online Article Text |
id | pubmed-9905027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99050272023-02-08 Enduring neurological sequelae of benzodiazepine use: an Internet survey Huff, Christy Finlayson, A. J. Reid Foster, D. E. Martin, Peter R. Ther Adv Psychopharmacol Discontinuing Psychotropic Medications INTRODUCTION: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated. OBJECTIVE: This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation. METHODS: An online survey (n = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms. RESULTS: The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal. CONCLUSIONS: These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users. SAGE Publications 2023-02-06 /pmc/articles/PMC9905027/ /pubmed/36760692 http://dx.doi.org/10.1177/20451253221145561 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Discontinuing Psychotropic Medications Huff, Christy Finlayson, A. J. Reid Foster, D. E. Martin, Peter R. Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title | Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title_full | Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title_fullStr | Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title_full_unstemmed | Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title_short | Enduring neurological sequelae of benzodiazepine use: an Internet survey |
title_sort | enduring neurological sequelae of benzodiazepine use: an internet survey |
topic | Discontinuing Psychotropic Medications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905027/ https://www.ncbi.nlm.nih.gov/pubmed/36760692 http://dx.doi.org/10.1177/20451253221145561 |
work_keys_str_mv | AT huffchristy enduringneurologicalsequelaeofbenzodiazepineuseaninternetsurvey AT finlaysonajreid enduringneurologicalsequelaeofbenzodiazepineuseaninternetsurvey AT fosterde enduringneurologicalsequelaeofbenzodiazepineuseaninternetsurvey AT martinpeterr enduringneurologicalsequelaeofbenzodiazepineuseaninternetsurvey |